[End therapeutic nihilism towards COPD].

MMW Fortschr Med

Schwepunkts Pneumologie/ Allergologie/Schlaf-medizin, Med. Poliklinik, Universitätsklinikum Bonn.

Published: March 2007

Similar Publications

It has proven difficult to establish robust evidence for significant clinical benefits of medical treatment in primary sclerosing cholangitis (PSC). For ursodeoxycholic acid, clinical practice guidelines only offer vague recommendations, leading to a situation of variable prescription rates depending on local reimbursement policies and physician preference. The difficulty in drug development in PSC is partly related to a poor understanding of critical disease processes with failure to identify relevant mechanisms of action of putative drugs.

View Article and Find Full Text PDF

Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions.

Circulation

November 2024

Faculté de Médecine, Inserm UMR_S 999, HPPIT, Service de Pneumologie et Soins Intensifs Respiratoires, ERN-LUNG, Hôpital Bicêtre (Assistance Publique-Hôpitaux de Paris), Université Paris-Saclay, Le Kremlin-Bicêtre, France (M.H.).

View Article and Find Full Text PDF
Article Synopsis
  • Patients experiencing post-anoxic status epilepticus (PASE) after cardiac arrest face poor outcomes due to a combination of therapeutic nihilism and the difficulty in managing their seizures, which creates a bleak outlook.
  • This negative cycle is exacerbated by the exclusion of hypoxic-ischemic causes from clinical trials, limiting the development of effective treatments for these patients.
  • Early treatment with vigabatrin, which inhibits the breakdown of GABA, shows promise as it may enhance the effectiveness of other GABA-targeting medications in managing PASE.
View Article and Find Full Text PDF

Optimal Blood Pressure Targets with Age.

Clin Geriatr Med

November 2024

Division of Geriatrics, Spencer Fox Eccles School of Medicine, Center on Aging, University of Utah, 30 North Mario Capecchi Drive, 2nd Floor North, Salt Lake City, UT 84112, USA. Electronic address:

The focus of antihypertensive therapy in older adults should be on lowering the systolic blood pressure (SBP) to the patient's "optimal" benefit-based target goal. Applying benefit-based therapy to the majority of adults aged 65 years or older who are at high cardiovascular disease or cognitive impairment risk favors an SBP goal of less than 130 mm Hg, and for some, a goal of 120 mm Hg may be considered.

View Article and Find Full Text PDF

Detecting Alpha-1 Antitrypsin Deficiency: Current State, Impediments, Opportunities, and Future Directions.

Ann Am Thorac Soc

September 2024

Cleveland Clinic Foundation, Pulmonary, Allergy andCritical Care, Cleveland, Ohio, United States;

Alpha-1 antitrypsin deficiency (AATD) is an under-recognized condition with only a small minority of affected individuals detected, long delays between initial symptoms and diagnosis, and evidence that affected individuals may see many physicians with suggestive symptoms before an initial diagnosis is made. In the context that failure to detect AATD confers harm and that specific therapy is currently available, there is a clear need for enhanced detection. Impediments to enhanced detection include inadequate knowledge about AATD by physicians caring for at-risk patients, inattention to guidelines which endorse testing, a sense of therapeutic nihilism among some physicians (i.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!